Synlett 2023; 34(04): 353-358
DOI: 10.1055/s-0042-1751410
letter

Synthesis of N–C Fused Bicyclic 1,3,5-Triazinane-2,4-dione Derivatives from Saturated Ring-Fused Urazoles

a   Syngenta Biosciences Private Limited, Santa Monica Works, Corlim, Goa, 403110, India
c   Department of Chemistry, Mangalore University, Mangalagangothri, 576119, India
,
Roger G. Hall
b   Syngenta Crop Protection AG, Schaffhauserstrasse, 4332 Stein, Switzerland
,
Ashok Shyadligeri
a   Syngenta Biosciences Private Limited, Santa Monica Works, Corlim, Goa, 403110, India
,
Shrikant A. Shete
a   Syngenta Biosciences Private Limited, Santa Monica Works, Corlim, Goa, 403110, India
,
Bhanu N. Manjunath
a   Syngenta Biosciences Private Limited, Santa Monica Works, Corlim, Goa, 403110, India
› Institutsangaben


Abstract

A synthesis of novel bicyclic 1,3,5-triazinane-2,4-diones has been accomplished through base-promoted fragmentation followed by cyclization. Various saturated ring-fused bicyclic urazoles were prepared by two complementary methods: by the reaction of N,N′-bis(2-chloroethyl)urazoles with various nucleophiles or by using 4-substituted urazoles and dibromoalkanes. Treatment of these symmetrical urazole derivatives with LDA at –78 °C to 25 °C resulted in fragmentation of the N–N bond to form an imine that underwent intramolecular cyclization, resulting in moderate yields of nonsymmetric heterocycle derivatives with an asymmetric (racemic) center and various ring sizes. The utility of these transformations was extended to syntheses of a tricyclic system and bicyclic systems containing additional heteroatoms.

Supporting Information



Publikationsverlauf

Eingereicht: 11. November 2022

Angenommen nach Revision: 28. Dezember 2022

Artikel online veröffentlicht:
24. Januar 2023

© 2023. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References and Notes

    • 1a Walsh CT. Tetrahedron Lett. 2015; 56: 3075
    • 1b Heravi MM, Zadsirjan V. RSC Adv. 2020; 10: 44247
    • 1c Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB. Molecules 2020; 25: 1909
    • 1d Kharb R, Shahar Yar M, Sharma PC. Curr. Med. Chem. 2011; 18: 3265
    • 2a Singh S, Mandal MK, Masih A, Saha A, Ghosh SK, Bhat HR, Singh UP. Arch. Pharm. (Weinheim, Ger.) 2021; 354: 2000363
    • 2b Maliszewski D, Drozdowska D. Pharmaceuticals 2022; 15: 221
  • 3 Coats SJ, Dyatkin AB, He W, Lisko J, Miskowski TA, Ralbovsky JL, Schulz M. WO 2007079214, 2007
  • 4 Thuemmler W, Hoppe A, Jahn H, Ikier H, Kemter P, Kochmann W, Kryslak P, Niess R, Steinke W, Thust U. DD 241414, 1986
  • 5 Zhang G.-J, Li B, Cui H.-M, Chen L, Tian Y, Liu S.-J, Li B.-W, Li M, Xia Z.-M, Chen X.-X, Hou Y, Dong JX. Org. Lett. 2018; 20: 656
  • 6 Freidinger RM, Evans BE, Bock MG. US 5177071, 1993
  • 7 Watanabe Y, Usui H, Kobayashi S, Yoshiwara H, Shibano T, Tanaka T, Kanao M. J. Med. Chem. 1992; 35: 189
  • 8 Sheradsky T, Moshenberg R. J. Org. Chem. 1984; 49: 587
    • 9a Sheradsky T, Moshenberg R. J. Org. Chem. 1985; 50: 5604
    • 9b Tanaka S, Seguchi K, Itoh K, Sera A. Bull. Chem. Soc. Jpn. 1996; 69: 3533
    • 9c Tanaka S, Seguchi K. Chem. Lett. 1998; 27: 1135
    • 9d Tanaka S, Seguchi K. Mukogawa Joshi Daigaku Kiyo, Shizen Kagaku-hen 2010; 58: 1
    • 9e Seguchi K. Mukogawa Joshi Daigaku Kiyo, Shizen Kagaku-hen 2012; 60: 11
    • 10a Adam W, Grabowski S, Hinz RF, Lucchini V, Peters E.-M, Peters K, Rebollo H, von Schnering HG. Chem. Ber. 1987; 120: 2075
    • 10b Beniazza R, Desvergnes V, Girard E, Kauffmann B, Berlande M, Landais Y. Chem. Eur. J. 2012; 11976
  • 11 Panga SR, Hall RG, Montgomery M, Samant RV, Shyadligeri AS. Tetrahedron Lett. 2022; 106: 154076
    • 12a Makino K, Henmi Y, Terasawa M, Hara O, Hamada Y. Tetrahedron Lett. 2005; 46: 555
    • 12b Wei Y, Lemal DM. Org. Lett. 2004; 6: 3837
    • 12c Chai W, Chang Y, Buynak JD. Tetrahedron Lett. 2012; 53: 3514
    • 12d Saluja P, Khurana JM, Sharma C, Aneja KR. Aust. J. Chem. 2014; 67: 867
    • 12e Zhu M, Kim MH, Lee S, Bae SJ, Kim SH, Park SB. J. Med. Chem. 2010; 53: 8760
  • 13 N–C Fused Perhydrotriazine-2,4-dione Derivatives 19a–g; General Procedure A 0.5 M solution of LDA (freshly prepared from butyllithium and diisopropylamine) in toluene (1.5 mmol, 1.5 equiv) was added to a 0.4 M solution of the appropriate fused urazole derivative 18ag (1.0 mmol, 1.0 equiv) in toluene at –78 °C. The mixture was slowly brought to 25 °C and stirred for 5 h. When the reaction was complete, the mixture was cooled to 0 °C and sat. aq NH4Cl was added. The resulting mixture was diluted with H2O (10 mL) and EtOAc (50 mL), and the organic layer was separated and washed successively with H2O and brine, dried (Na2SO4), and concentrated. The resulting crude product was triturated with EtOAc.
  • 14 3-(4-Chlorophenyl)hexahydro-2H-pyrido[1,2-a][1,3,5]triazine-2,4(3H)-dione (19a) White solid; yield: 72 mg (52%); mp 215–218 °C. 1H NMR (400 MHz, DMSO-d 6): δ = 8.36 (s, 1 H), 7.41–7.48 (m, J = 8.6 Hz, 2 H), 7.19–7.24 (m, J = 8.6 Hz, 2 H), 4.61 (br d, J = 6.7 Hz, 1 H), 4.00–4.12 (m, 1 H), 2.66–2.77 (m, 1 H), 1.85–1.94 (m, 1 H), 1.79 (br s, 1 H), 1.64 (br d, J = 12.1 Hz, 1 H), 1.42–1.53 (m, 2 H), 1.13–1.41 (m, 1 H). 13C NMR (101 MHz, DMSO-d 6): δ = 152.9, 151.6, 135.6, 132.4, 132.1, 128.7, 63.9, 43.6, 32.8, 24.1, 22.4. HRMS (ESI): m/z calcd for [C13H14ClN3O2]+: 279.0774; found: 279.0777.
    • 15a Gong Y, Bausch MJ, Wang L. Heterocycles 2001; 55: 163
    • 15b Gong Y, Bausch MJ, Wang L. Tetrahedron Lett. 2001; 42: 1
    • 15c Bartholomew D, Kay TI. J. Chem. Res., Synop. 1977; 239